Literature DB >> 22075004

Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.

Polly E Kintzel1, Alan D Campbell, Kathleen J Yost, Brett T Brinker, Nicole V Arradaza, Daniel Frobish, Alison M Wehr, Timothy J O'Rourke.   

Abstract

PURPOSE: Hydration and urinary alkalinization are essential for reducing renal dysfunction with high dose methotrexate (HDMTX). This report presents an analysis of institutional methods used to achieve adequate urinary alkalinization and output for patients receiving single agent HDMTX. Renal and metabolic parameters of tolerance were examined.
METHODS: Medical records of adult patients receiving HDMTX during the calendar years of 2008-2009 were retrospectively reviewed to determine the time to achieve urine pH > 7. Number of hospital days, bicarbonate dose, ordered hydration rate, urine output, and urine pH were assessed. A survival analysis model was run for time to urine pH > 7 using preadmission oral bicarbonate as a predictor variable and including a frailty term. Observational statistics were performed for other parameters.
RESULTS: The analysis included 79 encounters for ten patients. Urine pH > 7 was achieved more rapidly in patients receiving preadmission oral bicarbonate (P = 0.012). The number of patients receiving HDMTX on the same day as admission was greater for those receiving preadmission oral bicarbonate (47%) in comparison to those who did not (2%), and they spent less time in the hospital. A standard regimen for hydration and urinary alkalinization based on this project is reported. The nature and frequency of adverse events were as expected for this treatment.
CONCLUSION: At our institution, the time to achieve urinary alkalinization was reduced for patients receiving preadmission oral bicarbonate which facilitated chemotherapy infusion on the same day as admission and decreased the number of calendar days that patients stayed in the hospital.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075004     DOI: 10.1177/1078155211426913

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  4 in total

1.  Improved pharmacy department workflow with new method of order entry for single-agent, high-dose methotrexate.

Authors:  Polly E Kintzel; Thomas H VanDyke; Paul W Athmann; Lisa B Mills; Michael P Bonter; Matthew W Bremer; Mary L Dougherty; Ryan W Foster; Sandra K Knight; Martha G Slot; Laura L Steinmetz-Malato
Journal:  Hosp Pharm       Date:  2014-12

Review 2.  Fluid Stewardship of Maintenance Intravenous Fluids.

Authors:  John R Carr; W Anthony Hawkins; Andrea Sikora Newsome; Susan E Smith; Clemmons Amber B; Christopher M Bland; Trisha N Branan
Journal:  J Pharm Pract       Date:  2021-04-08

3.  A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate.

Authors:  Daniel R Reed; Eric J Pierce; Jeremy M Sen; Michael K Keng
Journal:  Cancer Manag Res       Date:  2019-08-30       Impact factor: 3.989

4.  Acute Kidney Injury Following High-Dose Methotrexate Administration in a Day Care Hospital.

Authors:  Srimanta Chandra Misra; Alberto Santagostino; Gerard Dine; Larence Bonhomme Faivre
Journal:  Drug Saf Case Rep       Date:  2019-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.